Neurofibromatosis Type 1: Symptoms, Causes, Diagnosis, and Treatment

What Is Neurofibromatosis Type 1 (NF1)?

What Is Neurofibromatosis Type 1 (NF1)?
Lana Way/Shutterstock

Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin, nervous system, and other parts of the body. The condition, formerly called Von Recklinghausen disease, causes changes in skin pigmentation and leads to the growth of benign (noncancerous) tumors on nerves, called neurofibromas. These tumors can develop on the skin, in the brain and spinal cord, and throughout the body. NF1 may also affect the eyes, bones, and learning abilities.

The condition is the most common form of neurofibromatosis and occurs in about 1 in 3,000 births worldwide each year. While symptoms can vary widely, the most visible features include light to dark brown skin spots known as café au lait macules, and soft lumps under the skin caused by neurofibromas.

Types of Neurofibromatosis

Neurofibromatosis type 1 is a type of neurofibromatosis, which are complex genetic conditions that can affect many different organ systems in the body. The hallmark feature of these conditions is the tendency for noncancerous (benign) tumors to develop on the nerves, spine, brain, and skin. The two other types of neurofibromatosis are neurofibromatosis type 2 and schwannomatosis.

Within NF1, there is also a less common variation called segmental NF1. This occurs when a genetic change (mutation) happens after conception, leading to symptoms that only appear in one area or segment of the body.

Signs and Symptoms of Neurofibromatosis Type 1

Symptoms of NF1 are usually seen at birth or shortly afterward — almost always by age 10. Which symptoms a person has and the severity of the symptoms can vary from person to person.

Symptoms may include:

  • Flat, Light-Brown Spots on the Skin Called café au lait spots, these spots are harmless. They are common in many people, but more than six of them suggests NF1. Café au lait spots are usually present at birth or develop during the first few years of life and stop appearing after childhood.
  • Freckles in Skin Folds Small clusters of freckles appear in areas such as the armpits, groin, or under the breasts.
  • Neurofibromas These are soft, pea-size or larger lumps under or on the skin. They are noncancerous nerve tumors and may increase in number with age.
  • Plexiform Neurofibromas These are larger tumors that grow along nerves or involve bundles of nerves. While they are initially benign, they can sometimes become cancerous over time.

  • Eye Changes Growths on the iris called Lisch nodules can occur, as can tumors along the optic nerve (optic gliomas), which may affect vision.
  • Bone Abnormalities These may include curved leg bones, scoliosis (curved spine), larger-than-average head size (macrocephaly), and shorter stature.

  • Neurological Symptoms These can include learning disabilities, developmental delays, attention deficit hyperactivity disorder (ADHD), headaches, and sometimes seizures.
  • Other Health Issues High blood pressure, chronic pain, and difficulty moving when tumors press on organs or nerves can all occur in HAE.

In addition to these symptoms, people with NF1 have an increased lifetime risk of developing both benign and malignant tumors, including optic pathway gliomas in children and, less often, cancers such as sarcomas or breast cancer.

Causes and Risk Factors of Neurofibromatosis Type 1

About half of people with NF1 inherit the condition from one of their parents. It can be inherited from a parent in an autosomal dominant pattern, meaning just one altered gene is enough to cause the condition. As a result, there is about a 50 percent chance that a person with NF1 will pass it on to their children.

The other half of cases are caused by a spontaneous change, or mutation (without any family history), in the NF1 gene, which normally makes neurofibromin, a protein that helps control how nervous system cells grow and divide. When it doesn’t work properly, cells can grow too quickly and form tumors.

The condition can vary widely, even within the same family. Some people have mostly skin spots and mild symptoms, while others develop more serious complications. Unlike many health conditions, NF1 is not caused by lifestyle or environment; the risk depends only on whether the NF1 gene mutation is present.

How Is Neurofibromatosis Type 1 Diagnosed?

If NF1 isn’t diagnosed at birth, parents often seek a diagnosis for their children because they notice the café au lait spots, says Roy Strowd, MD, a professor of neurology at Wake Forest University School of Medicine and a codirector of the neurofibromatosis clinic at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina.

Vision changes caused by tumors usually lead adults who develop NF1 to seek a diagnosis.

“While NF1 is a genetic condition, we actually use our clinical exam to establish a diagnosis,” says Dr. Strowd. A clinical diagnosis is when a doctor figures out what illness or condition you have on the basis of your symptoms, your medical history, and a physical exam.

“For a formal diagnosis, patients must have at least two of the characteristic diagnostic findings that we can identify on our clinical exam,” says Strowd.

Those findings include:

  • Six or more café au lait spots
  • Freckling in the armpit or groin
  • Two or more neurofibromas or one plexiform neurofibroma
  • Two or more Lisch nodules or iris hamartomas (bumps on the iris of the eye)
  • Optic pathway glioma
  • Curving of the bones of the shin
  • An NF1-associated gene variant on genetic testing
  • A parent with NF1

Common Diagnostic Procedures

Diagnostic procedures and tests that are used to diagnose NF1 include:

  • Imaging tests, including an MRI, X-ray, or CT scan
  • Genetic testing
  • An eye exam

Treatment for Neurofibromatosis Type 1

There is no cure for the NF1 condition as a whole, but treatments are available for most of the symptoms a person may have or develop, says Rebecca Brown, MD, PhD, an associate professor at the University of Alabama at Birmingham Department of Neurology and the director of the UAB Neurofibromatosis Clinic.

Medical Care and Monitoring

People with NF1 should have a yearly medical checkup and an annual eye exam to look for changes that may signal new problems.

Blood pressure should be checked regularly, since high blood pressure is more common in NF1.

Targeted Treatments

MEK inhibitors are a new class of drugs approved to treat inoperable plexiform tumors, which grow along the nerves in 30 to 50 percent of people with NF1.

Mirdametinib (Gomekli) inhibits MEK1/2, which are key mediators in the mitogen-activated protein kinase (MAPK) pathway. Overactivation of the MAPK pathway causes uncontrolled cell growth and tumor formation.

In clinical trials, 41 percent of adults and 52 percent of children had a shrinkage in the volume of their tumors. Participants also reported improvement in pain and health-related quality of life.

Selumetinib (Koselugo) works by blocking the RAS/RAF/MEK pathway, which is overactive in tumor cells, and has been shown to shrink inoperable tumors.

 The drug is currently approved in pediatric patients ages 1 year and older.

In clinical trials, 68 percent of children had tumor size reduction anywhere from 20 to 60 percent. Participants also reported better physical function, reduced pain, and improved mobility.

While the drug is not yet approved in adults, clinical trials in adults show tumor shrinkage in the majority of participants. Researchers are hopeful that with a successful phase 3 trial, the drug will be approved for use in adults.

Cancer Treatment

Chemotherapy or radiation therapy may be used to prevent tumors from growing or to treat tumors that have become cancerous.

Potential Future Treatments

There is ongoing research testing gene therapies for neurofibromatosis type 1. One potential treatment includes replacing the NF1 gene to restore the function of neurofibromin.

Surgery

If a tumor is growing, causing symptoms or pain, or there is a concern about cancer, it may be surgically removed.

Surgery or orthopedic braces (or both) may be necessary to correct some types of bone malformations, such as scoliosis.

Physical and Occupational Therapy

Some people with NF1 need assistance with walking, balance, and coordination, which may be helped with physical or occupational therapy.

Learning and Therapeutic Support

Children with NF1 have a higher risk of learning disabilities, including ADHD and delayed speech, and they should be evaluated by a professional who is knowledgeable about NF1. They may benefit from an individualized educational plan.

Light Therapy

There is some evidence that light therapy with topical vitamin D may help fade café au lait spots.

Prevention of Neurofibromatosis Type 1

There aren’t any known controllable risk factors to prevent NF1. Genetic counseling is recommended for people who have NF1 or who know they carry the gene for NF1.

Complications of Neurofibromatosis Type 1

People with NF1 have a higher risk of complications, including:

  • Attention deficit hyperactivity disorder (ADHD)
  • Blindness caused by a tumor in an optic nerve (optic nerve glioma)
  • Fracture in the leg bones that does not heal well
  • Loss of function in nerves that a neurofibroma has put pressure on over the long term
  • Tumors of the face and other exposed areas

  • Heart and blood vessel problems, including congenital heart defects, high blood pressure, narrowed kidney arteries, or narrowed brain blood vessels
  • Spinal issues, such as a severe form of scoliosis (curved spine)
  • Higher risk of certain tumors, including digestive system tumors, hormone-related tumors, and some benign nerve tumors
  • Breast cancer risk, which is increased in women with NF1 before age 50

What Is the Outlook for Neurofibromatosis Type 1

Because of the wide range in the number and severity of symptoms, spots, and tumors, NF1 affects each person differently. For some people, symptoms are manageable and don’t get in the way of everyday life. In people with more severe NF1, vision problems and pain can limit activity and require more medical care.

People with NF1 have a normal life expectancy and fertility for the most part, says Dr. Brown. “The big exception is for people who develop cancer or an aggressive brain tumor. While we cannot predict who will be affected in the future, we can keep close tabs on the health of the whole body for people with NF1 and try to catch and treat any concerning tumors early,” Brown says.

The same goes for skin, heart, and gut health, she adds. “There is a lot to keep track of, but the experts in this field are up to the ‘heaving lifting.’”

When to See a Doctor for Neurofibromatosis Type 1

Because NF1 is a lifelong condition, regular monitoring is important. Parents should contact their child’s doctor if they notice café au lait spots, unusual freckling, or soft lumps under the skin. Adults with NF1 should see a healthcare provider if they develop new symptoms, such as sudden changes in vision, pain, weakness, or rapid growth of a tumor.

Routine checkups with doctors familiar with NF1 — often a neurologist, geneticist, or NF specialty clinic — can detect complications early.

Research and Statistics: How Many People Have Neurofibromatosis Type 1?

NF1 is the most common type of neurofibromatosis. Each year, about 1 in 3,000 babies are born with the condition.

 In the United States, this means roughly 100,000 people are currently living with NF1.

Because symptoms vary widely, some people may go undiagnosed until later in life. Increased awareness and access to genetic testing have improved diagnosis rates in recent decades.

Conditions Related to Neurofibromatosis Type 1

There are some conditions that are more common in people with NF1.

  • Hypertension (High Blood Pressure) In NF1, blood vessels can be affected, making high blood pressure more common.
  • ADHD Many children with NF1 have changes in brain development that make attention and focus harder.
  • Scoliosis NF1 can affect bone growth, which increases the risk of abnormal spine curves.

The Takeaway

  • Neurofibromatosis type 1 (NF1) is a genetic condition that causes skin changes, noncancerous tumors on nerves, and, in some cases, learning or bone issues.
  • While there is no cure, regular medical checkups and monitoring can help manage symptoms and catch complications such as vision problems, high blood pressure, or tumor growth early.
  • New treatments, including targeted drugs like MEK inhibitors, are showing promise in shrinking large tumors and improving quality of life for people with NF1.
  • Most people with NF1 have a normal life expectancy, though there is a higher risk of certain cancers, making ongoing care with specialists especially important.

Common Questions & Answers

Who is at risk for neurofibromatosis type 1 (NF1)?
Anyone can develop NF1. The condition affects people of all races and genders. The main risk factor is having a parent with NF1, but it can occur even when there’s no family history.
No. There is currently no cure for NF1, but treatments are available to manage symptoms and complications, and ongoing research is exploring new therapies.
Most people with NF1 will develop some type of benign neurofibroma, but the number, size, and severity vary greatly. Some people only have a few, while others develop many throughout their lives.
Most NF1-related tumors are benign. But people with NF1 have a higher risk of developing certain cancers, including malignant peripheral nerve sheath tumors, breast cancer before age 50 in women, and some types of brain tumors.
Yes. Most people with NF1 have a normal life expectancy and can live full, active lives. Regular medical care helps manage complications, and early treatment improves quality of life.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Types of Neurofibromatosis. NYU Langone Health.
  2. Genetics of NF. Children’s Tumor Foundation.
  3. Neurofibromatosis Type 1 (NF1). Cleveland Clinic. November 29, 2023.
  4. Neurofibromatosis. National Institute of Neurological Disorders and Stroke. February 13, 2025.
  5. Plexiform Neurofibromas in Neurofibromatosis Type 1. Children’s Tumor Foundation.
  6. Moertel CL et al. ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. Journal of Clinical Oncology. November 8, 2024.
  7. Drug Shrinks Nerve Tumors in Adults with Neurofibromatosis Type 1 in a Clinical Trial. National Cancer Institute. January 6, 2025.
  8. FDA Approves Selumetinib for Pediatric Patients 1 Year of Age and Older With Neurofibromatosis Type 1 With Symptomatic, Inoperable Plexiform Neurofibromas. U.S. Food & Drug Administration. September 10, 2025.
  9. Gross AM et al. Selumetinib in Children With Inoperable Plexiform Neurofibromas. The New England Journal of Medicine. March 18, 2020.
  10. Potential of Gene Therapy for NF1-PN. AJMC. July 25, 2025.
  11. Support for Neurofibromatosis. NYU Langone Health.
  12. Nakayama J et al. Vitamin D3 and Neurofibromatosis Type 1. A Critical Evaluation of Vitamin D-Clinical Overview. April 26, 2017.
  13. Neurofibromatosis-1. Penn Medicine.
  14. Neurofibromatosis Type 1. Mayo Clinic. September 10, 2024.
  15. Neurofibromatosis Type 1 and Cancer Susceptibility. National Cancer Institute.
Anna-Hurst-bio

Anna C.E. Hurst, MD, MS, FACMG

Medical Reviewer
Anna C. E. Hurst, MD, is a medical geneticist with board certification in clinical genetics and pediatrics. She is an associate professor in the department of genetics at University of Alabama at Birmingham (UAB) and an adjunct faculty member at the HudsonAlpha Institute for Biotechnology. Prior to medical school, she received a master’s degree in genetic counseling, which inspired her interest in the communication of genetic information to patients and families with rare diseases.

Dr. Hurst is a physician for the UAB Undiagnosed Disease program, Turner syndrome clinic, and general genetics clinic, and she provides hospital consultations for inpatients at UAB and Children’s of Alabama for general genetics and inborn errors of metabolism. She also is the medical geneticist for the Smith Family Clinic for Genomic Medicine in Huntsville, Alabama.

Hurst's research focuses on expanding the availability of genomic sequencing for children with complex healthcare needs. She also has an interest in how the patient’s physical exam and facial features can be clues to a rare disease diagnosis (dysmorphology) and serves on the scientific advisory board of Facial Dysmorphology Novel Analysis. She has published over 45 peer-reviewed articles in the field of medical genetics, largely focused on the clinical delineation of rare disease phenotypes. She also serves as an associate editor for the American Journal of Medical Genetics.

Hurst is also passionate about education and serves as the program director of the UAB genetics residency programs (categorical, pediatrics-genetics, and internal medicine-genetics) and medical director of the UAB Genetic Counseling Training program. She is an officer with the Association of Professors in Human Medical Genetics.
Becky Upham, MA

Becky Upham

Author

Becky Upham has worked throughout the health and wellness world for over 25 years. She's been a race director, a team recruiter for the Leukemia and Lymphoma Society, a salesperson for a major pharmaceutical company, a blogger for Moogfest, a communications manager for Mission Health, a fitness instructor, and a health coach.

Upham majored in English at the University of North Carolina and has a master's in English writing from Hollins University.

Upham enjoys teaching cycling classes, running, reading fiction, and making playlists.